FOAMICON Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Foamicon, and what generic alternatives are available?
Foamicon is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in FOAMICON is aluminum hydroxide; magnesium trisilicate. There are one hundred and forty-one drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the aluminum hydroxide; magnesium trisilicate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for FOAMICON?
- What are the global sales for FOAMICON?
- What is Average Wholesale Price for FOAMICON?
Summary for FOAMICON
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 7 |
| Patent Applications: | 75 |
| DailyMed Link: | FOAMICON at DailyMed |
US Patents and Regulatory Information for FOAMICON
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | FOAMICON | aluminum hydroxide; magnesium trisilicate | TABLET, CHEWABLE;ORAL | 072687-001 | Jun 28, 1989 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
